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Heat shock proteins (Hsps) are highly expressed at all sites of inflammation. As they 
are ubiquitous and immunodominant antigens, these molecules represent good candi-
dates for the therapeutic use of oral tolerance in autoimmune and chronic inflammatory 
diseases. Evidences from human and animal studies indicate that inflammatory bowel 
disease (IBD) results from uncontrolled inflammatory responses to intestinal microbi-
ota. Hsps are immunodominant proteins expressed by several immune cells and by 
commensal bacteria. Using an IBD mouse model, we showed that oral pretreatment 
with genetically modified Lactococcus lactis that produces and releases Mycobacterium 
Hsp65, completely prevented DSS-induced colitis in C57BL/6 mice. Protection was 
associated with reduced pro-inflammatory cytokines, such as IFN-γ, IL-6, and TNF-α; 
increased IL-10 production in colonic tissue; and expansion of CD4+Foxp3+ and 
CD4+LAP+ regulatory T cells in spleen and mesenteric lymph nodes. This effect was 
dependent on IL-10 and toll-like receptor 2. Thus, this approach may open alternative 
options for long-term management of IBD.
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inTrODUcTiOn
The intestine is the largest surface of contact between the body and the external environment. It 
represents a major gateway for potential pathogens and also contacts an extensive and diverse micro-
biota and dietary antigens toward which tolerance must be induced (1). As such, the gut-associated 
lymphoid tissue is primarily a tolerogenic environment, and several cell types mediate regulatory 
activity in the gut mucosa. This includes regulatory T cells (Tregs) subsets such as Th3 cells, which 
produce TGF-β, and T regulatory 1 cells that produce IL-10 and CD4+CD25+ Tregs, which are 
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characterized by the expression of the transcription factor fork-
head box p3 (Foxp3) (2, 3). Maintenance of homeostasis is critical 
to the preservation of health and defects in mucosal tolerance 
leading to chronic disorders such as inflammatory bowel disease 
(IBD) (4).
Inflammatory bowel diseases, including Crohn’s disease (CD) 
and ulcerative colitis (UC), are idiopathic human syndromes 
marked by unrestrained gastrointestinal inflammation (5, 6) that 
causes diarrhea, abdominal pain, weight loss, and nausea (7). In 
Western societies, 1 in 1,000 individuals is affected by IBD, mak-
ing it an important public health problem. Although the causes 
for IBD are multiple, it likely involves an inappropriate immune 
response to the commensal microbiota in a genetically predisposed 
host (8, 9). Abundant clinical and laboratory research has shown 
that commensal bacteria harbored within mammalian intestines 
are the targets of inflammatory responses in IBD patients (10). In 
addition, recent studies identified a detectable difference between 
the intestinal microbiota present in individuals with CD and UC 
when compared to healthy controls. Thus, several evidences sug-
gest that a breakdown in the immune tolerance to the microbiota 
is central to the development of disease (10–12).
Currently, treatments are mainly focused on remission induc-
tion. The drugs usually prescribed include aminosalicylates, 
corticosteroids, immune modifiers, and antibiotics. Although 
many patients manage successfully the disease progression with 
conventional medical therapy, some stay refractory to treatment, 
most will have recurrent activity of disease, and in some cases, 
surgery may be required (13). One of the challenges for the 
development of new therapeutic strategies is the fact that the 
target antigen involved in the initiation and/or perpetuation of 
the disease is unknown (14). Since inflamed tissues express high 
levels of heat shock proteins (Hsps), these antigenic molecules are 
promising candidates for an immune-based IBD therapy. Hsps are 
intracellular chaperones that play an important role in preventing 
unwanted protein aggregation during folding and subunit assem-
bly (15–17). Expression of Hsps can be markedly upregulated by 
all cells under stress conditions including increased temperature, 
exposure to pro-inflammatory mediators, and oxidative stress 
(18, 19). Indeed, Hsp expression is increased in colon of IBD 
patients and antibodies as well as pathological T cells reactive to 
self-Hsp60 have been identified in these individuals (20, 21).
Although found to be a target self-antigen in autoimmun-
ity, Hsps are also involved in the body’s homeostasis. Self-Hsp 
reactive T and B cell clones can be seen as important parts of 
a network of regulatory cells in the immune system engaged in 
homeostasis activities, including tissue maintenance and repair as 
well as the control of inflammation (22–24). Hsp60 has a strong 
effect in the survival and function of CD4+CD25+Foxp3+ Treg 
(25). Consistent with this, anti-inflammatory effects of Hsp in 
autoimmune disease models such as rheumatoid arthritis (26), 
type I diabetes (27), multiple sclerosis (28), and atherosclerosis 
(29) have been reported. Recently, our group showed that 
Hsp65-producing Lactococcus lactis (Hsp65-LL) ameliorated 
experimental autoimmune encephalomyelitis (EAE) in mice, an 
effect mainly mediated by LAP-expressing Tregs (30).
Since oral tolerance is a potent way of inducing regulatory cells 
toward specific antigen (31), the idea of using the oral route to 
trigger tolerance to an antigen involved in autoimmune or inflam-
matory diseases comes as an important clinical application of the 
phenomenon (14, 32, 33). Our group has already shown that oral 
tolerance is more efficiently induced by continuously feeding 
the antigen. This regimen of feeding, rather than a single dose of 
antigen administered by gavage, is able to suppress inflammatory 
responses and autoimmune disease models even in aged mice 
(34–36). Two major caveats in this protocol of feeding are the 
difficulties of such procedure and the amount of antigen needed. 
We used a new strategy to deliver an endotoxin-free form of 
Hsp65 directly to the gut mucosa in a continuous feeding fashion 
by a recombinant L. lactis strain (37). L. lactis is a non-pathogenic, 
non-invasive, non-colonizing gram-positive bacterium, which 
was recently described as presenting probiotic properties, and 
mainly used to produce fermented food (38). L. lactis associated 
with alloantigens is able to induce antigen-specific tolerance to 
graft-versus-host disease more efficiently than the soluble antigen 
(39). Consistent with this, genetically modified L. lactis to secret 
other heterologous proteins, such as IL-10 (40), anti-TNF nano-
body (41), and Yersinia LcrV protein (42), has been successfully 
applied to IBD experimental models.
In this study, we demonstrate that Hsp65-LL can completely 
prevent Dextran sodium sulphate (DSS)-induced colitis in mice. 
Mechanistically, the immunomodulatory effect of Hsp65-LL is 
associated with induction of CD4+Foxp3+ and CD4+LAP+ Tregs, 
and it requires IL-10 and toll-like receptor 2 (TLR2) pathways.
aniMals anD MeThODs
animals
C57BL/6 mice were obtained from Universidade Federal de Minas 
Gerais (UFMG), Brazil. TLR4−/−, TLR2−/−, MAL/TIRAP−/−, and 
MyD88−/− (in C57BL/6 background) were kindly provided by 
Dr. Sergio Costa (UFMG, Belo Horizonte, Brazil), and IL-10−/− 
(in 129  Sv/Ev background) was provided by Dr. Donna Marie 
McCafferty (Calgary University, Calgary, AB, Canada). All mice 
were maintained in a specific pathogen-free facility at UFMG, 
Brazil. All animal procedures were performed in accordance 
with the guidelines from Conselho Nacional de Controle de 
Experimentação Animal (Brazil, http://www.mct.gov.br/index.
php/content/view/310553.html) and approved by the University 
Ethical Committee for Animal Research (Protocol # 114/2010, 
CEUA-UFMG, Brazil).
construction of hsp65-ll
As described elsewhere (43), a recombinant L. lactis strain 
NCDO2118 able to secrete Mycobacterium leprae Hsp65, using 
a xylose-inducible expression system, was constructed. The con-
structed vector (pSEC:hsp65) directed the expression of Hsp65 
to the extracellular medium. L. lactis NCDO2118 harboring an 
empty vector (pXylT:SEC without hsp65) was used as a negative 
control in all experiments.
Bacterial strains and growth conditions
The L. lactis NCDO2118 strains were grown in M17 broth 
(Difco, Detroit, MI, USA) supplemented with 0.5% glucose 
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(GM17) or 1% xylose (XM17; Synth, São Paulo, São Paulo, 
Brazil) at 30°C, without agitation. When required, chloram-
phenicol (10 µg/ml; Sigma-Aldrich, St. Louis, MO, USA) was 
added to the media.
conditions of Xylose induction
On the first day, a single colony of recombinant L. lactis har-
boring an empty vector (pXylT:SEC) or recombinant L. lactis 
NCDO2118 (pXylT:SEC:hsp65) was grown at 30°C, without 
agitation, in 5  ml GM17 containing chloramphenicol (Cm, 
10 µg/ml). On the second day, the overnight culture was diluted 
1:10,000 in 1% xylose fresh M17 (XM17) supplemented with 
Cm (10 µg/ml) to provide ideal conditions for bacterial growth 
and M. leprae hsp65 gene expression. On the third day, when an 
optical density of 2.0 at 600 nm was reached, which corresponds 
to 2.5 × 108 CFU/ml, mice treatment was performed.
L. lactis administration
During 4  days, C57BL/6, IL-10−/−, TLR4−/−, TLR2−/−, MAL/
TIRAP−/−, MyD88−/− mice were continuously fed either medium 
(control group) empty-vector-bearing L. lactis (CT-LL) or M. 
leprae-Hsp65-LL. Fresh L. lactis total culture (bacteria plus 
supernatant) obtained as previously described was offered to 
mice daily. Since each mouse drank about 5 ml of culture per day 
(data not shown) containing 7 µg/ml (44) of M. leprae Hsp65, the 
total dose of bacteria per mouse was estimated to be 5 × 109 CFU 
and the total daily dose of M. leprae Hsp65 was about 35 µg per 
mouse.
Oral Treatment with Zymosan
Alternatively, animals received 35 µg of zymosan (Sigma-Aldrich, 
St. Louis, MO, USA) dissolved in 5 ml fresh empty-vector-bearing 
L. lactis NCDO2118 total culture per day during 4  days as a 
control for Hsp65-LL.
colitis induction by Dss
Ten days after the last day of oral treatment with Hsp65-
producing L. lactis, control L. lactis, or zymosan, sex- and 
age-matched animals received 1.5% (w/v) DSS (40  kDa, ICN 
no. 160110; MP Biomedicals, Santa Ana, CA, USA) in the 
drinking water, ad libitum, for 7 days to induce colonic inflam-
mation (colitis). The amount of DSS and water consumed per 
animal was monitored; there was no marked difference between 
experimental groups.
Macroscopic and Microscopic 
assessment of colitis
Macroscopic score of DSS-induced colitis was derived by sepa-
rately scoring three major clinical signs, which were weight loss, 
diarrhea, and rectal bleeding, 7 days after DSS administration as 
described by Murthy et al. (45). Loss of body weight was calculated 
as the difference between the initial and actual weight. Diarrhea 
was showed as mucus/fecal material adherent to anal fur. The 
presence or absence of diarrhea was confirmed by examination 
of the colon following completion of the experiment. Mice were 
sacrificed and the colons were excised. Diarrhea was defined by 
the absence of fecal pellet formation in the colon and the presence 
of continuous fluid fecal material in the colon. Rectal bleeding 
was defined as diarrhea containing visible blood and gross rectal 
bleeding and scored as described for diarrhea. The macroscopic 
score was calculated from the score of the clinical signs using the 
following formula: (weight loss score) + (diarrhea score) + (rec-
tal bleeding score). Samples of colon were fixed in formalin and 
processed for microscopic analysis. Hematoxylin-eosin (Doles, 
Panamá, Goias, Brazil)-stained sections were blindly scored based 
on a semi-quantitative scoring system described previously (46) 
where the following features were graded: extent of destruction 
of normal mucosal architecture (0 represents normal; 1, 2, and 3 
represent mild, moderate, and extensive damage, respectively); 
presence and degree of cellular infiltration (0 represents normal; 
1, 2, and 3 represent mild, moderate, and transmural infiltration, 
respectively); extent of muscle thickening (0 represents normal; 
1, 2, and 3 represent mild, moderate, and extensive thickening, 
respectively); presence or absence of crypt abscesses (0 represents 
absent; 1 represents present); and the presence or absence of 
goblet cell depletion (0 represents absent; 1 represents present). 
Scores for each feature were summed up to a maximum possible 
score of 11.
colon Tissue Preparation and cytokine 
assay
The colon was washed with PBS and placed in a buffer solution 
(1 ml/g) containing Tween-20 0.05% (Sigma-Aldrich, St. Louis, 
MO, USA), phenylmethylsulfonyl fluoride 0.1  mM (Sigma-
Aldrich, St. Louis, MO, USA), benzethonium chloride 0.1 mM 
(Sigma-Aldrich, St. Louis, MO, USA), EDTA 10 mM (Synth, São 
Paulo, São Paulo, Brazil), and aprotinin A 20 KIU (Sigma-Aldrich, 
St. Louis, MO, USA). Then, it was homogenized, centrifuged at 
3,000 g for 10 min and the supernatants collected for cytokine 
assay. Plates were coated with purified monoclonal antibod-
ies reactive with cytokines IL-6, TNF-α, TGF-β (active form), 
IFN-γ, IL-4, IL-17, and IL-10 (BD Bioscience, San Jose, CA, 
USA), overnight at 4°C. In the following day, wells were washed, 
supernatants were added, and plates were incubated overnight 
at 4°C. On the third day, biotinylated monoclonal antibodies 
against cytokines (BD Bioscience, San Jose, CA, USA) were added 
and plates were incubated for 2  h at room temperature. Color 
reaction was developed at room temperature with 100 μl/well of 
orthophenylenediamine 1 mg/ml (Sigma-Aldrich, St. Louis, MO, 
USA), 0.04% H2O2 substrate in sodium citrate buffer. Reaction 
was interrupted by the addition of 20  μl/well of 2  N H2SO4. 
Absorbance was measured at 492 nm by ELISA reader (Bio-Rad, 
Hercules, CA, USA).
Measurement of intestinal iga
Levels of IgA were determined in the intestinal lavage. Small 
intestine was rinsed with 10  ml of cold PBS. Intestinal lavages 
were centrifuged at 12,000 g for 20 min at 4°C, and levels of IgA 
in the supernatants were determined by ELISA. Briefly, 96-well 
plates were coated with Ig goat anti-mouse unlabeled antibody 
in coating buffer (pH 9.6) overnight at 4°C. Wells were washed 
and blocked with 200 µl PBS containing 0.25% casein for 1 h at 
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room temperature. Samples were added to the plates and incu-
bated for 1 h at 37°C. The plates were then washed, peroxidase-
streptavidin goat anti-mouse IgA-HRP (Southern Biotechnology, 
Birmingham, AL, USA) diluted 1:10,000 was added, and the 
plates were incubated for 1  h at 37°C. Color was developed at 
room temperature with 100 μl/well of orthophenylenediamine 
(1 mg/ml; Sigma-Aldrich, St. Louis, MO, USA) and 0.04% H2O2 
substrate in sodium citrate buffer. The reaction was interrupted 
by the addition of 20  μl/well of 2  N H2SO4. Absorbance was 
measured at 492 nm using an ELISA microplate reader (Bio-Rad, 
Hercules, CA, USA).
lamina Propria (lP) cell isolation
Lamina propria cells were isolated by a modified version of the 
method described by Davies and Parrot (47). Briefly, the entire 
length of large intestine was dissected, opened longitudinally, 
washed with PBS, and cut into small pieces. Tissue fragments were 
placed in Petri dishes and washed three times in calcium- and 
magnesium-free HBSS containing 1 mM dl-dithiothreitol (DTT; 
Sigma-Aldrich, St. Louis, MO, USA) for 30  min. Supernatants 
were discarded. After that, tissue fragments were incubated with 
100 µl/mL of collagenase II (Sigma-Aldrich, St. Louis, MO, USA) 
for 60 min at 37°C on a shaker. Supernatants were passed through 
a 70 µm cell strainer (Falcon, Corning, NY, USA) and then resus-
pended in medium. Cells isolated from LP were then submitted 
to flow cytometry labeling.
Flow cytometry analysis
Fluorescein isothiocyanate-conjugated mAbs to CD4 (clone 
RM4-5, IgG2a); phycoerithrin (PE)-conjugated mAbs to CD4 
(clone RM4-5, IgG2a); CD45Rb (clone 16A, IgG2a); Foxp3 
(clone R16-715, IgG2a); PE-Cy5-conjugated mAbs to CD4 
(clone RM4-5, IgG2a); PerCP-Cy5.5 mAbs to CD25 (clone PC61, 
IgG1); biotin-conjugated mAbs to CD25 (clone 7D4, IgM); 
streptavidin-Cy5-chrome and streptavidin-allophycocyanin 
(APC), rat IgG1, IgG2a, IgG2b, and IgM isotype controls were 
purchased from BD Biosciences (San Jose, CA, USA). The biotin 
anti-LAP antibody (clone BAF246, IgG) was purchased from 
R&D Systems (Minneapolis, MN, USA). Surface staining was 
performed according to standard procedures at a density of 
0.5–1 × 106 cells per 25 µl, and volumes were scaled up accord-
ingly. For Foxp3 staining, cells were fixed in Fix/Perm buffer 
(eBioscience, San Diego, CA, USA) after the surface staining, 
followed by permeabilization in Perm buffer (eBioscience, San 
Diego, CA, USA) and staining for PE-anti-Foxp3 according to 
the manufacturer’s instructions. Samples were acquired in a 
FACSCan or in a FACSCalibur cytometer (BD Biosciences, San 
Jose, CA, USA) and analyzed using the FlowJo software (TriStar, 
San Carlos, CA, USA). At least 30,000 events were acquired for 
each sample.
statistical analysis
Results were expressed as the mean ±  SEM. Normal distribu-
tion of samples was confirmed by the Kolmogorov–Smirnov 
test. Significance of differences among groups was determined 
by Student’s t-test or analysis of variance (Tukey’s post hoc test). 
Means were considered statistically different when p < 0.05.
resUlTs
Oral administration of hsp65-ll 
Prevented colitis in Mice
We previously constructed a recombinant L. lactis strain 
able to produce and secrete Hsp65 from M. leprae. This L. 
lactis-expressing Hsp65 preparations contained less endotoxin 
(lipopolysaccharide, LPS) than the limit set by the Food and 
Drug Administration (34). To verify the efficacy of this new 
therapeutic concept, C57BL/6 wild-type (WT) mice were con-
tinuously fed Hsp65-LL for 4 consecutive days. The total dose 
of bacteria per mouse was estimated to be 5 × 109 CFU and the 
total daily dose of M. leprae Hsp65 was about 35 µg per mouse. 
The control groups received either medium (CT) or empty 
vector-bearing L. lactis (CT-LL). After 10 days, mice received 
1.5% DSS dissolved in drinking water during 7 days to induce 
colitis (Figure 1A). We showed that DSS-induced colitis led to 
colon shortening in mice, which was prevented by the pretreat-
ment with Hsp65-L. lactis (Figure 1B). Macroscopically, mice 
fed Hsp65-L. lactis showed similar score (weight loss, diarrhea, 
and rectal bleeding) to naïve mice (Figure 1C). DSS-induced 
colitis caused epithelial damage, loss of goblet cells, and crypts, 
and cellular infiltration starting at day 3. Accordingly, the his-
tological score, devised to allow quantification of histological 
changes, revealed that pretreatment with Hsp65-L. lactis com-
pletely prevented the loss of mucosal architecture and inflam-
matory cell infiltration in mucosa and submucosa layers of the 
mice (Figures 1D,E).
Oral administration of hsp65-ll 
Maintained Physiological levels of 
cytokine Production in colonic Tissue
We started investigating the mechanisms involved in colitis pre-
vention by Hsp65-LL by assessing whether oral administration 
of this recombinant bacterium could alter cytokine production 
in colon tissue. The chosen cytokines are either implicated in 
the pathogenesis of IBD (IL-6, TNF-α, IL-4, IFN-γ, or IL-17) or 
have anti-inflammatory activity (IL-10 and TGF-β1). Cytokines 
were measured in the colonic tissue homogenates after 7 days of 
DSS administration. We found that levels of IL-6, TNF-α, and 
IL-4 were increased in the CT group, but they resembled the 
naïve group in Hsp65-L. lactis-treated mice (Figures 2A,B,D). 
Mice pretreated with empty vector-bearing L. lactis showed 
intermediate levels of these cytokines (Figures  2A,D). IL-17 
production did not change in any group when compared 
with naïve mice, whereas IFN-γ levels were increased by DSS 
administration, but not reduced by the oral pretreatments 
(Figures 2C,F). The increase of TGF-β1 levels observed in the 
CT group was prevented by the pretreatment with Hsp65-L. 
lactis (Figure  2E). However, IL-10, an important cytokine 
involved in the homeostasis of gut mucosa (48), was kept close 
to physiological levels (naïve group) after pretreatment with 
Hsp65-L. lactis. Conversely, IL-10 levels found in the CT and 
CT-LL groups were reduced (Figure 2G). Thus, Hsp65-L. lactis 
oral treatment maintained most of the cytokines measured at 
physiological levels.
FigUre 1 | effect of hsp65-producing L. lactis (hsp65-ll) on Dss-induced colitis. (a) Experimental protocol and experimental groups. Groups of five 
C57BL/6 mice were pretreated or not (naïve) with medium (CT), empty vector-harboring L. lactis (CT-LL), or Hsp65-LL for four consecutive days. Ten days later, mice 
received 1.5% DSS in drinking water for 7 days. (B) Colon lengths were measured after 7 days of colitis induction. (c) Macroscopic scores including body weight 
loss, stool consistency, and bleeding were calculated at day 7. (D,e) At day 7, colons were collected and dissected for histological analysis by hematoxylin and 
eosin staining. Histological scores (sum of loss of mucosal architecture, cellular infiltration, muscle thickening, crypt abscess formation, and goblet cell depletion) 
were ranked blindly. (e) Representative distal colon section of naive group (non-treated wild-type mice), CT + DSS, CT-LL + DSS, and Hsp65-LL + DSS. Results 
are representatives of four independent experiments. Bar graphs are shown as mean ± SEM. Analysis of variance, Tukey’s post hoc test, p < 0.05. Distinct letters 
are used to distinguish groups that are statistically different.
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Secretory IgA exerts protective functions in the intestinal 
mucosa such as improving gut immunological barrier and 
controlling commensal microbiota (49). Upregulation of its 
production is a possible mechanism of action for probiotic 
bacteria. Thus, our next step was to measure IgA in the intestinal 
lavage of mice. Neither acute colitis nor the oral pretreatment 
FigUre 2 | effect of hsp65-producing L. lactis (hsp65-ll) on cytokine production in colonic tissue. Groups of five C57BL/6 mice were pretreated or not 
(naïve) with medium (CT), empty vector-harboring L. lactis (CT-LL), or Hsp65-LL for four consecutive days. Ten days later, mice were given 1.5% DSS in drinking 
water for 7 days. Concentrations of cytokines were determined by ELISA. (a) IL-6, (B) TNF-α, (c) IFN-γ, (D) IL-4, (e) TGF-β, (F) IL-17, and (g) IL-10. Results are 
representatives of three independent experiments. Bar graphs are shown as mean ± SEM. Analysis of variance, Tukey’s post hoc test, p < 0.05 (N = 4). Distinct 
letters are used to distinguish groups that are statistically different.
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with either empty vector-bearing L. lactis or Hsp65-L. lactis 
affected intestinal IgA production (data not shown), suggesting 
that cytokine maintenance, particularly IL-10, at homeostatic 
levels rather than secretory IgA underlied the anti-colitogenic 
functions of oral treatment with Hsp65-L. lactis.
il-10 is required for the 
immunomodulatory effect of hsp65-ll
Since Hsp65-LL maintained the physiological levels of IL-10, we 
investigated whether the prevention of colitis by Hsp65-L. lactis 
was dependent on this anti-inflammatory cytokine. To address 
this question, 6-week-old IL-10-deficient (IL-10−/−) mice and 
WT mice were orally fed with either medium or Hsp65-LL for 
four consecutive days. Ten days later, colitis was induced by 
DSS administration. Different from what we observed in WT 
mice, macroscopic and histological scores did not change with 
Hsp65-L. lactis oral treatment in IL-10−/− mice (Figures 3A,B), 
revealing the importance of IL-10 in the protection from DSS-
induced colitis.
To confirm the involvement of IL-10 in the anti-colitogenic 
activity of Hsp65-LL, we tested whether the spontaneous colitis 
developed in IL-10−/− mice could be ameliorated by the Hsp65-L. 
lactis treatment. In this case, 4-week-old IL-10−/− mice were 
orally fed Hsp65-L. lactis for 4 consecutive days. Macroscopic 
and histological scores were evaluated after 6  weeks, when 
IL-10−/− mice show the signals of spontaneous colitis (48, 50). 
Despite the reduction in the macroscopic score when com-
pared with medium or empty vector-harboring L. lactis groups, 
Hsp65-LL was ineffective in improving the histological score of 
IL-10−/− mice colitis (Figures 3C,D). Thus, the IL-10 pathway 
is partially necessary for the Hsp65-LL immunomodulatory 
effect in the spontaneous colitis suggesting that other mecha-
nisms, such as the production of TGF-β1, may also be involved. 
Indeed, pretreatment of IL-10−/− mice with Hsp65-L. lactis led 
to an increase in TGF-β1 production in the colon tissue with 
no changes in IFN-γ or IL-17 (Figure  3E). Consistent with 
this, TGF-β levels were increased in extracts of colonic LP, 
and the frequency and absolute number of TGF-β1-producing 
FigUre 3 | anti-colitogenic effect of hsp65-producing L. lactis (hsp65-ll) is dependent on il-10. Groups of 6-week-old IL-10-deficient (IL-10−/−) mice or 
control (129Sv/Ev) mice were pretreated or not (naïve) with medium (CT) or Hsp65-LL for four consecutive days. Ten days later, mice were given 1.5% DSS in 
drinking water for 7 days. (a) Macroscopic score including body weight loss, stool consistency, and bleeding were scored at day 7. (B) At day 7, colons were 
collected and dissected for histological analysis by hematoxylin and eosin staining. Histological scores (sum of loss of mucosal architecture, cellular infiltration, 
muscle thickening, crypt abscess formation, and goblet cell depletion) were ranked blindly (N = 4). (c,D) Groups of 6-week-old IL-10-deficient mice were pretreated 
or not (naïve) with medium (CT), empty vector-harboring L. lactis (CT-LL), or Hsp65-LL for four consecutive days. When IL-10−/− mice completed 12 weeks of age, 
macroscopic and histological scores were ranked. (e) Cytokines such as IFN-γ, IL-17, and IL-10 were measured in colon extracts at the end of the experiment.  
(F) Lamina propria (LP) T cells from entire colon, cells isolated from mesenteric lymph nodes (mLNs) or from cecal lymph nodes (cLN) were obtained from 
IL-10−/− mice. Frequency of CD4+CD25+LAP+ T cells was assessed by flow cytometry and gated in the lymphocyte population (N = 8). Results are representatives of 
two independent experiments. Bar graphs are shown as mean ± SEM. Analysis of variance, Tukey’s post hoc test, p < 0.05. Distinct letters are used to distinguish 
groups that are statistically different. Asterisks are used in panels (a,B) to mark statistically significant differences between groups that received medium and 
Hsp65-LL.
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CD4+CD25+LAP+ Tregs were found augmented in the colonic 
LP (Figures  3E,F; Table S1 in Supplementary Material) of 
IL-10−/− treated with Hsp65-L. lactis. Taken together, these data 
suggest that IL-10 is crucial for the anti-colitogenic function of 
Hsp65-LL in DSS-induced colitis and at least partially involved 
in the prevention of spontaneous colitis in IL-10-deficient 
mice. In the complete absence of IL-10, TGF-β production 
increased probably as a compensatory mechanism to restore 
gut homeostasis.
Prevention of colitis by hsp65-ll is 
Dependent on Tlr2
Heat shock proteins have the capacity to interact with a variety of 
immune molecules at the cell surface such as toll-like receptors 
(TLRs), particularly TLR2 and TLR4 (18, 51). Accordingly, it 
has been shown that the signaling pathway induced by TLRs is 
involved in the immunomodulation by immune cells (18, 25, 51). 
To verify whether the TLR signaling cascade was indeed involved 
in the immunomodulation of colitis induced by Hsp65-L. lactis 
FigUre 4 | Toll-like receptor 2 (Tlr2) is required for the anti-
colitogenic effect of hsp65-producing L. lactis (hsp65-ll). (a) Groups 
of C57BL/6, TLR4−/−, and TLR2−/− mice were pretreated or not (naïve) with 
medium (CT), empty vector-harboring L. lactis (CT-LL), or Hsp65-LL for four 
consecutive days. Ten days later, mice were given 1.5% DSS in drinking 
water for 7 days. At day 7, colons were collected and dissected for 
histological analysis by hematoxylin and eosin staining. Histological scores 
(sum of loss of mucosal architecture, cellular infiltration, muscle thickening, 
crypt abscess formation, and goblet cell depletion) were ranked blindly. (B) 
IL-10 was measured in colon extracts at the end of the experiment. Results 
are representative of three independent experiments. Bar graphs are shown 
as mean ± SEM. Analysis of variance, Tukey’s post hoc test, p < 0.05 
(N = 4). Distinct letters are used to distinguish groups that are statistically 
different.
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in  vivo, we pretreated TLR2−/−, TLR4−/−, MAL/TIRAP−/−, and 
MyD88−/− mice with medium, empty-vector-bearing L. lactis 
(data not shown) or Hsp65-L. lactis. As shown in Figure  4A, 
oral administration of Hsp65-L. lactis significantly reduced the 
histological score in WT and TLR4−/− mice, but not in TLR2−/−, 
MAL/TIRAP−/−, or MyD88−/− mice, revealing the dependence 
of these molecules on Hsp65-L. lactis anti-colitogenic effects. 
Consistent with this, IL-10 production was maintained at physi-
ological levels after the pretreatment of WT mice with Hsp65-L. 
lactis, which did not occur in TLR2−/− mice (Figure  4B). To 
address whether a naturally occurring exogenous TLR2 ligand 
such as zymozan, a glucan prepared from yeast cell wall, would 
improve the DSS-induced colitis in a similar fashion than Hsp65, 
we compared the effect of Hsp65-L. lactis with zymozan at the 
same concentration (35 µg per mouse) dissolved in the CT-LL 
supernatant. As shown in Figure S1 in Supplementary Material, 
oral pretreatment with zymozan did not prevent colitis in mice, 
suggesting TLR2 ligand specificity in the immunomodulation 
induced by Hsp65-LL.
administration of hsp65-ll expands Treg
Since Hsp65-LL induced an anti-inflammatory cytokine profile 
in the colon, we next investigated whether Hsp65-LL would 
affect the frequency of Tregs. Recently, we showed that the 
pretreatment with Hsp65-LL modulates EAE in mice by induc-
ing CD4+Foxp3+ and CD4+LAP+ Tregs (30). In DSS-induced 
colitis model, the pretreatment of mice with Hsp65-LL increased 
the CD4+Foxp3+ cell frequency in the spleen when compared 
to naïve mice after 3  days of colitis induction (Figure  5A). 
Moreover, the reduced frequency of CD4+LAP+ cells observed 
in both CT and CT-LL groups was restrained by the Hsp65-L. 
lactis pretreatment (Figure  5B). Finally, we verified whether 
oral pretreatment of mice with Hsp65-L. lactis would be suf-
ficient to increase Tregs before the colitis induction and whether 
TLR2 would be involved in such effect. WT and TLR2−/− mice 
received the Hsp65-L. lactis by the oral route during 4  days, 
and 4 or 10 days after the last day of oral treatment we analyzed 
the frequencies and absolute numbers of Treg populations. 
We observed an increase in CD4+Foxp3+ (Figures  5C,D) and 
CD4+LAP+ (Figure  5E) cell frequencies and numbers (Tables 
S2 and S3 in Supplementary Material) in spleen and mesenteric 
lymph nodes (mLNs) of Hsp65-L. lactis fed mice 10 days after 
the oral treatment. However, such Treg increase in WT mice after 
Hsp65-L. lactis pretreatment was not observed in TLR2−/− mice, 
suggesting the involvement of TLR2 in the Treg expansion after 
Hsp65-L. lactis oral administration.
DiscUssiOn
Heat shock proteins constitute a functional class of highly 
homologous proteins found in all living organisms and upregu-
lated when cells are under stress (15). Apart from functioning 
as chaperones, Hsps also present immunoregulatory activities 
(24, 52). Consistent with this, it has been shown that mucosal 
administration of Hsp65-induced Tregs in several models of 
chronic inflammatory conditions such as atherosclerosis (29), 
rheumatoid arthritis (26), and diabetes (27). Since upregula-
tion of self-Hsps is part of the inflammatory response in many 
diseases, the induction of cross-reactive T cells against self-Hsp 
upon mucosal administration of the bacterial Hsp65, becomes 
an attractive explanation for the development of Tregs in the 
mucosa. This implies that Hsps may be a therapeutic target 
for the induction of mucosal tolerance in cases where the 
auto-antigen is unknown. This is particularly relevant in IBD 
because the disease is driven by an aberrant immune response to 
commensals (5).
The precise role of Hsps in IBDs remains unclear. Elevated 
levels of Heat shock protein 70 (Hsp70) have been found in 
human biopsies from active UC patients and correlated with 
disease severity (53). Polymorphisms in the Hsp70-2 gene have 
been reported as indicators of the clinical course of UC and CD 
(54). Autoantibodies to Hsp60 and 70 have also been detected 
in patients with IBD, supporting the concept of immune cross-
reactivity between prokaryotic and eukaryotic Hsps as the basis 
for disease pathogenesis (54). Interestingly, Leung and coworkers 
(55) demonstrated that in DSS-induced colitis model, luminal 
bacteria expressed Hsp60 after 3  days of DSS administration, 
whereas the Hsp60 expression appeared in macrophages at day 6 
and in damaged epithelial cells at day 15. Thus, the Hsp60 could 
be considered as a relevant antigen in IBD and also in DSS-
induced colitis.
FigUre 5 | hsp65-producing L. lactis (hsp65-ll) induces increased frequencies of regulatory T cells (Tregs) in mice. C57BL/6 mice were pretreated or 
not (naïve) with medium (CT), empty vector-harboring L. lactis (CT-LL), or Hsp65-LL for 4 days and colitis was induced 10 days later by 1.5% DSS in drinking water. 
Seventy-two hours after DSS administration, mice were sacrificed and mesenteric lymph nodes (mLNs) removed. Cells were stained with fluorescein isothiocyanate-
conjugated (FITC)-anti-CD4, PE-anti-Foxp3, Bio-CD25 and CY5.5-STV (a) or with FITC-anti-CD4, PE-anti-CD25, Bio-LAP, and Cy5.5-STV (B). Alternatively, 
C57BL/6 mice were orally pretreated or not (naïve) with Hsp65-LL during 4 days. Either 4 or 10 days after the last day of oral treatment frequencies of Treg 
populations were analyzed by flow cytometry. (c) Spleen and (D) mLN cells were stained with Cy5.5 anti-CD4 and PE anti-Foxp3. (e) Spleen cells were stained with 
Cy5.5 anti-CD4; biotin anti-LAP, and APC streptavidin. CD4+Foxp3+ and CD4+LAP+ cells were gated on lymphocyte population (N = 4). Results are representative of 
three independent experiments. Bar graphs are shown as mean ± SEM. Analysis of variance, Tukey’s post hoc test, p < 0.05. Distinct letters are used in panels 
(a,B) to distinguish groups that are statistically different. Asterisks are used in panels (c–e) to mark statistically significant differences between naïve group and the 
group that received Hsp65-LL.
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In this study, we showed that oral administration of Hsp65-LL 
prevented colitis development in mice and induced CD4+Foxp3+/
CD4+LAP+ Tregs in a TLR2/IL-10-dependent fashion. Although 
oral tolerance had been successfully used before in the treatment 
of experimental IBD (56), no study has yet demonstrated the 
effects of oral tolerance to Hsps in these diseases.
Recently, we demonstrated that oral administration of Hsp65-LL 
induced oral tolerance in the model of EAE in mice. Moreover, 
the effect was associated with increased IL-10 production in mLN 
and spleen cell cultures and Treg expansion in the same lymphoid 
organs (30). IL-10 is an important anti-inflammatory cytokine 
produced by Tregs and a variety of other cell types including epi-
thelia, activated macrophages, dendritic cells (DC), and B1 cells. 
The importance of this cytokine in shaping mucosal immune 
responses has been demonstrated by the spontaneous onset of 
gut inflammation in IL-10-deficient mice (47, 49). Accordingly, 
we showed that Hsp65-L. lactis prevented the reduction of IL-10 
in the colonic tissue, which was critical for the immunoregula-
tory effect induced by the Hsp65-LL in the DSS colitis model. 
Moreover, despite the improvement in macroscopic score and the 
increased levels of TGF-β1 and CD4+LAP+ Tregs found in the 
colonic tissue of 12-week-old IL-10−/− mice fed Hsp65-L. lactis, 
inflammatory cell infiltration in the colonic tissue was not pre-
vented by such treatment, pointing out the importance of IL-10 
in the immunomodulatory mechanisms induced by Hsp65-LL. 
Of note, in the spontaneous colitis developed by IL-10-deficient 
mice, it seems that other mechanisms may also play a role since 
oral administration of Hsp65-LL still had some protective effect. 
Since TGF- β1 production was upregulated in the colonic mucosa 
of these treated animals, it is plausible that, in a chronic inflam-
matory setting happening in the constitutive absence of IL-10, 
TGF-β1 acted as a compensatory anti-inflammatory mechanism.
Consistent with the important role of IL-10 in our study, 
Wieten and coworkers demonstrated that Hsp70 immunization of 
mice 10 days prior to proteoglycan-induced arthritis delayed the 
disease onset in an IL-10-dependent manner (26). Furthermore, 
as observed for IL-10, pro-inflammatory cytokines measured 
in the colon tissue of DSS-induced colitis mice pretreated with 
Hsp65-L. lactis were kept at physiological levels (when compared 
to non-manipulated naïve mice), suggesting that the main role 
of Hsp65-L. lactis is to maintain homeostasis in the gut mucosa.
As a stress protein and pathogen-associated molecular pattern, 
Hsps are mainly recognized by pattern-recognition receptors 
(PRR) present in immune cells, such as TLRs. TLRs comprise 
a class of transmembrane PRR that play a key role in microbial 
recognition, induction of antimicrobial genes and control of 
adaptive immune responses, being important for intestinal 
homeostasis regulation in both health and disease (57, 58). TLRs 
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are differentially expressed by many distinct cell types throughout 
the gastrointestinal tract, including intestinal epithelial cells and 
antigen-presenting cells (58). Moreover, Hsp60 has been shown 
to be an endogenous ligand for TLR2 and TLR4 (59). Consistent 
with this, we found that TLR2 expression was critical for the anti-
colitogenic activity of Hsp65-LL, since TLR2−/− mice as well as 
mice deficient for the TLR2 adaptor molecules MyD88 and MAL/
TIRAP, which mediate TLR2 signaling pathway (60), showed 
no improvement of colitis by the pretreatment of Hsp65-L. 
lactis. Thus, the immunomodulation induced by Hsp65-LL 
is completely dependent on TLR2 and the adaptor molecules 
involved in its signaling cascade. Hsp70 is also able to inhibit 
TNF-α, IFN-γ, and MCP-1 produced by bone marrow-derived 
DC by suppressing C/EBPβ and C/EBPδ transcription factors in 
a IL-10- and TLR2-dependent fashion (61), indicating that this 
may represent a conserved and common pathway of immune-
modulation by Hsps. Interestingly, the effect of Hsp70 was distinct 
from the effect of other TLR2 ligands classified as PAMPs such as 
bacterial peptideoglycan (61). We have also tested another TLR2 
ligand, zymosan, on its ability to reproduce the effects of Hsp65. 
Zymosan is a glucan with repeating glucose units connected 
by β-1,3-glycosidic linkages found on the surface of yeast (62). 
Zymosan was administered orally in combination with L. lactis at 
the same maximum concentration found for Hsp65 released by 
the recombinant strain (35 µg), and no effect on colitis develop-
ment was observed. This result suggests that, like Hsp70, binding 
of Hsp65 to TLR2 in cells at the gut mucosa triggered signaling 
pathways that are distinct from the ones induced by a typical 
PAMP. Zymosan-induced responses in macrophages include 
the production of pro-inflammatory cytokines, arachidonate 
mobilization, protein phosphorylation, and inositol phosphate 
formation (62). On the other hand, Hsps have been proposed to 
exert their function as resolution-associated molecular patterns 
(RAMPs) rather than PAMPs when binding TLRs. RAMPs are 
shown to counterbalance acute inflammation and restore immune 
homeostasis by modulating innate cells. After tissue damage, they 
can modulate acute inflammation by inducing the production of 
IL-10 (63). In a study comparing the in vitro effects of LPS-free 
Mycobacterium tuberculosis Hsp70 and of LPS on DC, Motta and 
coworkers demonstrated that Hsp70 effects were opposed to the 
ones triggered by LPS-contaminated Hsp70. In contrast to LPS, 
Hsp70 did induce neither DC maturation nor TNF-α production 
by these cells. Instead, it induced IL-10 secretion and inhibited 
T cell proliferation (64). It is plausible that endogenous ligands 
such as Hsps bind with distinct affinity to the same receptors or, 
alternatively, that PAMPs bind to distinct combination of TLRs 
and other receptors triggering different signaling pathways.
As for the effects of Hsp60, it has been shown that, by binding 
to TLR2, it leads to a decrease in TNF-α and IFN-γ production 
and an increase in IL-10 release by T cells. Hsp60 induces a strong 
effect in the survival and function of CD4+CD25+Foxp3+ Tregs 
(25) via TLR2. In addition, it efficiently drives the differentiation 
of CD4+CD25− T cell clones derived from juvenile idiopathic 
arthritis patients into CD4+CD25high Tregs (65). A similar ability 
to drive the differentiation of regulatory CD4+Foxp3+ Tregs and 
inhibiting inflammatory diseases such as arthritis and colitis has 
been associated with DC stimulated with Hsp70 (66). These data 
suggest that Hsps may serve as therapeutic targets for chronic 
inflammatory diseases.
We demonstrated that oral administration of Hsp65-LL 
restored the frequency of Tregs in mice subjected to DSS-induced 
colitis, and it also expanded Tregs in healthy (without colitis) 
mice. More importantly, these effects were completely abrogated 
in IL-10−/− and TLR2−/− mice, indicating that the Treg modula-
tion by Hsp65-LL is dependent on IL-10 production and TLR2 
activation. Because Hsp65 is highly analogous to the mammalian 
Hsp60 and L. lactis is a safe bacterium to be used in humans, 
this work supports the idea that Hsp65-LL may constitute an 
important tool for the treatment of IBDs. On one hand, it may be 
possible to take advantage of the ability of this protein to induce 
Tregs for clinical purposes. On the other hand, antigen delivery 
by a lactic bacterium with probiotic properties in a continuous 
feeding mode may add an adjuvant effect to the modulatory 
abilities of Hsp65.
aUThOr cOnTriBUTiOns
AG-S was responsible for planning and executing the experiments 
as well as writing the manuscript; RO and TM helped planning and 
executing of the experiments, AC-J, BH, and LL helped execut-
ing the experiments; LA helped with the experiments involving 
TLR signaling; RR helped planning many of the experiments, 
discussions, and writing the manuscript; SO helped planning 
the experiments with TLR pathway; VA and AM constructed the 
recombinant L. lactis and helped with planning the experiments; 
DC helped with histopathological analysis; AMCF designed and 
supervised the experiments and wrote the manuscript.
acKnOWleDgMenTs
The authors are grateful to Ilda Marçal de Souza e Hermes Ribeiro 
for the excellent care of the animals. This study had financial sup-
port from Fundação de Amparo à Pesquisa do Estado de Minas 
Gerais (FAPEMIG, Brazil, # APQ-00704-14). Some of the authors 
are recipients of scholarships (LL, BH, and AC-J) and research 
fellowships (AMCF # 307191/2006-0, AG-S and RO) from 
Conselho Nacional de Desenvolvimento Científico e Tecnológico 
(CNPq, Brazil).
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found 
online at http://journal.frontiersin.org/article/10.3389/fimmu. 
2017.00030/full#supplementary-material.
FigUre s1 | Oral administration of toll-like receptor 2 exogenous ligand 
does not prevent Dss-induced colitis in mice. C57BL/6 mice were 
pretreated or not with medium, Hsp65-producing L. lactis (Hsp65-LL), Hsp65-LL 
supernatant, or zymozan dissolved in L. lactis supernatant for 4 days and DSS 
was induced 10 days later. (a) Colon length was measured after 7 days of colitis 
induction. (B) Macroscopic score including body weight loss, stool consistency, 
and bleeding were scored on day 7. Bar graphs are shown as mean ± SEM. 
Analysis of variance, Tukey’s post hoc test (N = 4). Distinct letters are used in 
panels (a,B) to distinguish groups that are statistically different.
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